Company profile for Gritstone bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally-infected cells. It is well-established that one fundamental driver of an effective immune response is T cell recognition of abnormal cells a...
Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally-infected cells. It is well-established that one fundamental driver of an effective immune response is T cell recognition of abnormal cells and the proliferation of sufficient quantities of T cells to drive a potent attack against these cells, whether they are cancerous or virally-infected.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5959 Horton Street, Suite 300 Emeryville, CA 94608
Telephone
Telephone
(510) 871-6100
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/11/11/2978577/0/en/Gritstone-bio-Announces-Strengthening-of-Maturing-Phase-2-PFS-Data-for-GRANITE-Study-and-Provides-Business-Update.html

GLOBENEWSWIRE
11 Nov 2024

https://www.biospace.com/business/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research

BIOSPACE
11 Oct 2024

https://www.businesswire.com/news/home/20241009836692/en

BUSINESSWIRE
10 Oct 2024

https://www.globenewswire.com/en/news-release/2024/09/30/2955620/0/en/Gritstone-bio-Announces-Interim-Phase-2-Data-for-GRANITE-Individualized-Neoantigen-Targeting-Immunotherapy-in-Frontline-Metastatic-Microsatellite-Stable-Colorectal-Cancer.html

GLOBENEWSWIRE
30 Sep 2024

https://www.globenewswire.com/news-release/2024/08/13/2929622/0/en/Gritstone-bio-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Updates.html

GLOBENEWSWIRE
13 Aug 2024

https://www.globenewswire.com/news-release/2024/07/24/2917878/0/en/Gritstone-bio-to-Host-Virtual-KOL-Event-to-Discuss-Unmet-Need-and-Potential-Role-of-Its-Personalized-Cancer-Vaccine-GRANITE-in-Metastatic-Microsatellite-Stable-Colorectal-Cancer-MS.html

GLOBENEWSWIRE
24 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty